Navigation Links
WellPoint Reports Second Quarter 2009 Results
Date:7/29/2009

ith the sale of its NextRx subsidiaries, which is expected to close in the second half of 2009.

Investment Portfolio & Capital Position: During the second quarter of 2009, the Company recorded net investment losses of $58.3 million pre-tax, consisting of other-than-temporary impairments totaling $74.0 million, which were partially offset by net realized gains of $15.7 million.

As of June 30, 2009, the Company's net unrealized loss position was $34.4 million, consisting of net unrealized losses on fixed maturity securities of $52.7 million, partially offset by net unrealized gains on equity securities of $18.3 million.

As of June 30, 2009, statutory capital levels in the Company's insurance subsidiaries exceeded Blue Cross and Blue Shield Association requirements by approximately $2.4 billion and state regulatory levels by approximately $5.6 billion. Cash and investments at the parent company totaled approximately $1.4 billion.

REPORTABLE SEGMENTS

WellPoint, Inc. has the following reportable segments: Commercial Business, which includes the Local Group, National, UniCare, and Specialty Products lines of business; Consumer Business, which includes the Individual, Senior, and State Sponsored lines of business; and Other, which includes Comprehensive Health Solutions (including the Company's NextRx PBM operation), Federal Employee Program or "FEP" business, National Government Services, inter-segment sales and expense eliminations, and corporate expenses not allocated to the other reportable segments.

Operating revenue and operating gain are the key measures used by management to evaluate performance in each segment.

                                        WellPoint, Inc.
                                 Reportable Segment Highlights
                                          (Unaudited)

    (In mil
'/>"/>
SOURCE WellPoint, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine news :

1. WellPoint State Sponsored Business President Appointed Advisory Board Member of the HIMSS Board of Directors
2. WellPoints Contribution To Drug Formulary Evaluation Standards Highlighted in ISPOR Publication
3. WellPoint Recovers and Saves $75 Million Through Anti-Fraud Programs and Investigations in 2008
4. WellPoint Teams up with Bob Harper from The Biggest Loser to Expand Efforts Aimed at Improving Individuals Health
5. WellPoint Captures Gold for Its Associate Wellness Program
6. WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety, Efficacy and Compliance for Medicaid Members
7. WellPoint to Hold Conference Call and Webcast to Discuss Second Quarter Results on July 29, 2009
8. Woman Whose Health Insurance Was Cancelled by Blue Cross/WellPoint After She Got Sick Urges Congress to Protect Innocent Patients
9. IDGs Computerworld Names WellPoint to Annual List of Best Places to Work in Information Technology
10. Express Scripts Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of WellPoints NextRx Subsidiaries
11. WellPoint Announces Appearances at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 2014 Acute coronary syndrome (ACS) ... healthcare costs, frequent recurrences and hospitalizations, and high ... ACS incidence increases with age and will be ... population increases around the world. ACS is classified ... heart muscle damage inferred from a person’s symptoms, ...
(Date:7/14/2014)... 14, 2014 Georgia State University ... groups under the fifth round of its Second ... of research and academic performance. , The ... of top-notch faculty members to the university, with ... in areas of national significance. , “With the ...
(Date:7/14/2014)... through the bloodstream, homing in on a sheath ... and metastasize to other organs, scientists at The ... in Cancer Cell . , "This completely ... provides new potential avenues to predict and prevent ... M.D., professor of Gynecologic Oncology and Reproductive Medicine ...
(Date:7/14/2014)... look back on 40 years of the Glasgow Coma Scale ... and clinical practice, in a new Personal View published in ... Personal View is published on the 40th anniversary of the ... Since this seminal publication, the Glasgow Coma Scale has provided ... level, the clinical hallmark of acute brain injury. The scale ...
(Date:7/14/2014)... D.C., July 14, 2014 A recent study published ... of the American Academy of Child and Adolescent Psychiatry ... the age of onset criterion for diagnosis of attention-deficit/hyperactivity ... for ADHD, previously set at 7 in DSM-IV, has ... of onset is now set at 12, rather than ...
Breaking Medicine News(10 mins):Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 2Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 3Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 4Health News:Georgia State Starts Four Innovative Research Groups Through Fifth Round of Its Second Century Initiative 2Health News:Georgia State Starts Four Innovative Research Groups Through Fifth Round of Its Second Century Initiative 3Health News:MD Anderson researchers discover new route for ovarian cancer spread 2Health News:MD Anderson researchers discover new route for ovarian cancer spread 3
... a novel study on condom use with help from ,scientists, ... the significance of condom use in curtailing spread of AIDS. ... study on a request from Pope Benedict XVI. The cardinal ... abstinence from sex in the fight against AIDS. ...
... has been approved by the Food and Drug Administration ... cyanide poisoning//. The kit contains the drug hydroxocobalamin, intravenous ... enables emergency treatment for known or suspected cyanide poisoning. ... to emergencies including possible attacks by terrorists is enhanced. ...
... people seeking medical help because of illnesses related to alcohol ... few years//. ,Current official statistics show that ... treated for accidents and emergencies caused due to drunkenness ... for the same also have doubled, reported NHS since 1997, ...
... given rise not only to high expectations of treatment ... the German Research Foundation, Deutsche Forschungsgemeinschaft (DFG) issued its ... developed enormously. ,The second memorandum, which ... on Genetic Research, makes it clear that gene therapy ...
... research study finds that 95 percent of Americans have pre ... new as American men //and women as far back as ... disappointed that spending hundreds of millions of dollars advising young ... being wasted. One official disagreed and opined that even if ...
... ingredient of psychedelic mushrooms, also called magic mushrooms ... disorder (OCD), according to a study// by University ... substances like psilocybin, psilocin, or muscimol. ,The ... 1970, according to AP reports. ,The intent ...
Cached Medicine News:Health News:Gene Therapy for Hereditary Immunodeficiency Diseases 2
(Date:7/14/2014)... July 14, 2014  Mylan Inc. (NASDAQ: MYL ... agreement with Abbott (NYSE: ... non-U.S. developed markets specialty and branded generics business ("the ... will receive 105 million shares of the combined ... of $50.20 on Friday, July 11, 2014, representing an approximately ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... 11, 2010 Thoratec Corporation (Nasdaq: THOR ... therapies to save, support and restore failing hearts, said ... Tuesday, November 16 at the American Heart Association (AHA) ... and chief executive officer of Thoratec, will be discussing ...
... 2010 Ardea Biosciences, Inc. (Nasdaq: RDEA ... trials of BAY 86-9766 (formerly known as RDEA119) will ... and Treatment of Cancer (EORTC) – National Cancer Institute ... on "Molecular Targets and Cancer Therapeutics" in Berlin, Germany. ...
Cached Medicine Technology:Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 3Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 4